Public Company News

ASX listed cancer drug hopeful Pharmaust have secured additional IP rights to their highly promising anti-cancer drug Monepantel by partially trading off rights to another project under their control. Under the new deal, Pharmaust will receive the remainder of the IP rights to Monepantel that were never transferred to them by the University of NSW.

Analytica have patented their unique medical device in one of the worlds most populous markets. The People’s Republic of China recently granted Analytica’s patent application for the company’s “Peri-Coach" pelvic floor force sensing device. The Peri-Coach can eliminate urinary incontinence, a condition afflicting nearly 230m Chinese women according to the company. 

Well known mining focused private equity firm Resource Capital Funds has taken a plunge at ASX junior Hammer Metals with its latest $2b mining fund. RCF has taken a $1.75m placement in Hammer Metals at 7c a share representing the lion’s share of the company’s latest $2.25m capital raise. The funds will be spent on Hammer's100% owned Mt Isa copper gold project. 

Medical device company Analytica has attracted further interest from Virgin Islands based investment fund INOV8 who will stump up $500k at .007c a share to take their second placement in the company. INOV8 have tripled their $500k plunge at Analytica back in March when they successfully picked the bottom of the company’s share price graph at just .00255c a share.

In a sign that ASX listed Shark Mitigation Systems are getting serious about taking their unique shark deterring wetsuits to market, surf wear industry specialist Simon O’Sullivan has been appointed as General Manager of the company. O’Sullivan was most recently the Australian Chief Operating Officer of well known surf brand Rusty with responsibility for the Australian operations.  

With the gold price at record highs, Blackham Resources appear to have timed their transition from explorer to miner exquisitely. After a couple of years of excellent exploration success, the Bryan Dixon led Matilda Gold Project in Wiluna W.A is once again a mining operation. It is expected to churn out $300m in free cash over the next ten years and thats just the warm up period. 

Analytica have achieved patent protection in the world’s biggest medical device market for their unique “AutoStart Burette” medical device after receiving advice from the US Patent and Trademarks office that their patent had been granted and will be operable until the 17th January 2031. A "burette" is the little chamber that is inserted into a medical drip to administer medicine. 

Blackham Resources took a bit of a punt at the Matilda Gold project recently which looks like it may pay off. The company drilled their deepest hole yet at the project and intersected gold mineralization at over 400m with the hole still open at depth.  Deeper drilling results at the M1 pit of 2m @ 6.98 g/t from the 419m mark confirm the continuation of mineralization at depth.

Troy Resources recent drilling program from the pit floor at the Karouni gold mine in South America has turned up a number of stellar intersections including one grading over 4 ounces to the tonne gold with visible gold evident in a number of samples. Around half of the 29 drill intercepts from the latest program occured below the current pit design. 

ASX listed Analytica has received approval from the powerful US Food and Drug Administration to sell their unique “PeriCoach” incontinence medical device without the need for a prescription in the USA. The PeriCoach is a proprietary medical device developed by Analytica to assist women to exercise their pelvic floor muscles in order to reduce or eliminate urinary incontinence.

ASX listed nano-satellite developer Sky and Space Global has successfully applied to register their own frequency spectrum with the United Nations’ “International Telecommunications Union”. The company says registering its own frequency spectrum is a crucial element to cretaing their own nano-satellite based affordable global telecomminications network. 

The recently released feasibility study into Neometals' patented "Eli' process that downstream processes Lithium, shows that for a $158m capital outlay, the project will return a wave of cash averaging $82m a year before tax every year for the next 20 years. It shows a net present value of AUD$638m which equates to around $1.14 a share on a fully dispersed basis.